Scientific and corporate news
Stem cell enriched lipotransfer reverses the
effects of fibrosis in systemic sclerosis
Oro-facial fibrosis in systemic sclerosis (Scleroderma;SSc) has a major impact on mouth function, facial appearance, and patient quality of life. Lipotransfer is a method of reconstruction that can be used in the treatment of oro-facial fibrosis.
Intratendinous adipose-derived stromal vascular fraction (SVF) injection provides a safe, efficacious treatment for Achilles tendinopathy: results of a randomized controlled clinical trial at a 6-month follow-up
Purpose Although platelet-rich plasma (PRP) injection has shown controversial results for the treatment of Achilles tendinopathy, it remains the most used biological treatment. Recent findings seem to demonstrate that the stromal vascular fraction (SVF) within adipose tissue may counteract the impaired tendon homeostasis.
Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study
Stroke is a major cause of death and long-term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic
Safety and efficacy of intracoronary treatment with umbilical cord-derived mesenchymal stem cells for very elderly patients with chronic total coronary occlusion
This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord-derived mesenchymal stem cells in very elderly patients with chronic total coronary occlusion into the coronary artery that provides collateral circulation to the heart
Adipose-derived mesenchymal stem cells (AdMSCs) for the treatment of secondary progressive multiple sclerosis: A triple-blind, placebo-controlled, randomized phase I/II safety and feasibility study
Currently available treatments for secondary progressive multiple sclerosis (SPMS) have limited efficacy. Adipose-mesenchymal-derived stem cells (AdMSCs) represent a promising option and can be easily obtained
Stem Cell Storage: Intermediary companies fail, but there are still Biobanks to rely on like SSCB
“The failure and mismanagement of other Biobanks for Stem Cell Preservation ruin our sector”, speaks Dr. Luca Mariotta, Scientific Director of SSCB.
Last week, Ticinonews reported on a young couple who were looking for their baby’s cells after the company they had contracted with, Genico, disappeared. Cantonal pharmacist Giovan Maria Zanini said he was concerned about Switzerland’s free-market policy in such a sensitive area.